AmodSarnaikMD

Melanoma, Surgical Oncology (Other than Breast)

Physician

Overview of Dr. Sarnaik

Dr. Amod Sarnaik is a general surgeon in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. He received his medical degree from University of Michigan Medical School and has been in practice 18 years. Dr. Sarnaik accepts several types of health insurance, listed below. He is one of 93 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 39 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in General Surgery. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
# SRB-4
Tampa, FL 33612
Book by Phone+1(816) 656-2598

Fax+1 813-745-5725

Education & Training

University of Cincinnati Medical Center/College of MedicineResidency, Surgery, 1999 - 2006
University of Michigan Medical SchoolClass of 1999

Certifications & Licensure

FL State Medical License 2007 - 2026
OH State Medical License 1999 - 2006
American Board of Surgery Surgery

Clinical Trials

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma Start of enrollment: 2009 Oct 20
Active, not recruiting
Not Applicable
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Start of enrollment: 2010 Aug 13
Completed
Phase 1
Minimally Invasive Groin Dissection for Melanoma Start of enrollment: 2012 Jun 01
Completed
Not Applicable
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2012 Jul 27
Completed
Phase 1
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Start of enrollment: 2012 Aug 03
Active, not recruiting
Phase 2
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Start of enrollment: 2012 Oct 09
Active, not recruiting
Not Applicable
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study Start of enrollment: 2013 Jan 24
Completed
Phase 1
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Start of enrollment: 2014 Jan 07
Completed
Phase 1
Biomarker Correlates of Hypoxia in Metastatic Melanoma Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma Start of enrollment: 2016 Mar 08
Completed
Early Phase 1
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients Start of enrollment: 2020 Dec 22
Active, not recruiting
Phase 2
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Start of enrollment: 2021 Oct 22
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma.
Ahmad A Tarhini, Zeynep Eroglu, Islam Eljilany, Jonathan S Zager, Ricardo J Gonzalez
Clinical Cancer Research. 2024-12-02
1 citations
Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy.
Zachary Z Reinstein, Yue Zhang, Oscar E Ospina, Matt D Nichols, Victoria A Chu
Cancer Discovery. 2024-09-04
2 citations
Tumor-infiltrating lymphocytes: A new hope.
Amod A Sarnaik, Patrick Hwu, James J Mulé, Shari Pilon-Thomas
Cancer Cell. 2024-08-12

Journal Articles

Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?
C Wayne Cruse, Vernon K Sondak, Ricardo J Gonzalez, Daniel E Oliver, Jane L Messina, Louis B Harrison, Jonathan S Zager, Amod A Sarnaik, Annals of Surgical Oncology
Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
Jonathan S Zager, Amod A Sarnaik, Annals of Surgical Oncology
Resection Margins in Merkel Cell Carcinoma: Is a 1-Cm Margin Wide Enough?
Daniel E Oliver, Vernon K Sondak, C Wayne Cruse, Louis B Harrison, Ricardo J Gonzalez, Amod A Sarnaik, Jonathan S Zager, Jane L Messina, Annals of Surgical Oncology

Lectures

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on m...
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Tumor-Infiltrating Lymphocyte Therapy: A Milestone in Cancer TreatmentJuly 19th, 2024
Moffitt Cancer Center on Cutting Edge of New Treatment That Could Save Lives of Advanced Melanoma PatientsNovember 22nd, 2022
Combo T Cell and Targeted Therapy Strategy for Resistant Melanoma with BRAF MutationFebruary 18th, 2019
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Aetna Whole Health Banner Health Network
AvMed Health Open Access
BCBS Arizona BlueAlliance Network
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Health Net Arizona HMO
Health Net Arizona HMO ExcelCare Network
Health Net Arizona PPO/POS
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment